Lilly's Asset Management Program
Executive Summary
Eli Lilly & Co.'s recent explosion of dealmaking in the seemingly disparate areas of combinatorial chemistry and drug delivery are in fact closely linked by Lilly's approach towards asset management.
You may also be interested in...
Inside Lilly Research Laboratories: A Discussion With Jan Lundberg
Unbowed by a string of recent pipeline setbacks, Lilly Research Labs' new leader speaks out about his company's current trajectory and his belief in ongoing initiatives like Chorus and a mirror fund as Lilly attempts to bridge its patent cliff.
EU Advances Plans For New Catalogs Of RWD Sources & Non-Interventional Studies
Users of the new catalogs will benefit from a modern technology with enhanced view, search, export and data submission functionalities, says the European Commission.
US Court Says Yes To Gilead’s Quarter Billion Dollar Settlement On Truvada, Atripla
Despite winning a landmark multi-billion-dollar antitrust suit earlier this year, Gilead Sciences has seen a US court give an initial green light allowing it to shell out nearly $250m to settle antitrust claims from direct purchasers of its two major HIV drugs.